WuXi ATU Opens New Facility in Philadelphia for Advanced Therapies Testing
WuXi Advanced Therapies, a wholly owned subsidiary of WuXi AppTec, has announced the official launch of its testing facility located in Philadelphia’s Navy Yard.
The new facility with 140,000 square feet of labs, will improve the firm’s Contract Testing, Development, and Manufacturing Organization business model by expanding the previous testing capacity. This will allow the company to meet the growing demands of customers in the cell gene therapy market.
WuXi ATU has opened this new facility as an expansion of its existing Navy Yard Campus (opened in 2020). The expansion is aimed to improve the existing analytical development and testing capacity and capability.
Wuxi ATU operates globally as a CTDMO and has a unique business model which integrates testing capabilities with its advanced therapies’ process development and manufacturing platforms including TESSA technology for AAV manufacturing and XLenti stable solutions for lentiviral manufacturing. This enables assay development, biosafety, viral clearance and product release testing to be completed in-house, shortening customers’ timelines for the approval of advanced therapies. The CTDMO has supported more than 1,700 customer submissions for biosafety testing through industry-leading testing and analytical assay development experience, enabling the delivery of more effective and accessible advanced therapies to patients.
About WuXi Advanced Therapies (WuXi ATU)
WuXi Advanced Therapies (ATU) is a business unit of WuXi AppTec dedicated to advanced therapies for Contract Testing, Development and Manufacturing. The company offers integrated platforms to enhance the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies. For more information, please visit www.advancedtherapies.com